Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126892731 | 12689273 | 1 | I | 20081015 | 20151204 | 20160826 | 20160826 | EXP | GB-ROCHE-1820080 | ROCHE | 55.00 | YR | F | Y | 0.00000 | 20160826 | MD | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126892731 | 12689273 | 1 | PS | CAPECITABINE. | CAPECITABINE | 1 | Unknown | U | 20896 | TABLET | |||||||||
| 126892731 | 12689273 | 2 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | U | 0 | ||||||||||
| 126892731 | 12689273 | 3 | SS | SARGRAMOSTIM | SARGRAMOSTIM | 1 | Unknown | U | 0 | ||||||||||
| 126892731 | 12689273 | 4 | C | CREON | PANCRELIPASE AMYLASEPANCRELIPASE LIPASEPANCRELIPASE PROTEASE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126892731 | 12689273 | 1 | Pancreatic carcinoma metastatic |
| 126892731 | 12689273 | 2 | Pancreatic carcinoma metastatic |
| 126892731 | 12689273 | 3 | Pancreatic carcinoma metastatic |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126892731 | 12689273 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126892731 | 12689273 | Biliary tract infection | |
| 126892731 | 12689273 | Device occlusion |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |